Search

Voclosporin

Within 10 years of being diagnosed with SLE, 5-20% of those suffering from LN develop end-stage kidney disease, a fatal condition. … LN is a significant cause of renal failure, morbidity, and death in patients with SLE.

Dihydrocodeine

It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis … It was marketed in 1911.

Garadacimab

[L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan. … [L53283] It was developed by CSL Behring for use as a prophylactic agent in patients with hereditary angioedema (HAE), a rare autosomal dominant disorder that results in acute episodes of angioedema.

Brilliant blue G

Brilliant blue G, like its name, imparts a vibrant blue color, facilitating identification of the ILM. It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830] … Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures.

Cinoxate

Vericiguat

Vericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and hospitalizations. … to its structure have dramatically decreased its susceptibility to oxidative metabolism,[A227458] resulting in a relatively long half-life and allowing for once-daily dosing.

Sparsentan

Sparsentan is a dual antagonist of the endothelin type A receptor (ET_AR) and the angiotensin II (Ang II) type 1 receptor (AT₁R) with a similar affinity for both (9.3 nM for ET<sub … >A</sub>R antagonist.

Human papillomavirus type 16 L1 capsid protein antigen

Human papillomavirus type 16 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces

Human papillomavirus type 18 L1 capsid protein antigen

Human papillomavirus type 18 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces

Acetohexamide

A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.